APA (7th ed.) Citation

Dean, A., Harris, M., Sjoquist, K., Gebski, V., Karapetis, C., Lomma, C., . . . Price, T. (2025). 2219P AGITG ASCEND: Randomised, double-blind phase II trial of certepetide (CERT) or placebo (PLA) with gemcitabine (Gem) + nab-paclitaxel (Nab) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated results including planned pooled placebo analysis. Annals of Oncology, 36, S1233. https://doi.org/10.1016/j.annonc.2025.08.2836

Chicago Style (17th ed.) Citation

Dean, A., et al. "2219P AGITG ASCEND: Randomised, Double-blind Phase II Trial of Certepetide (CERT) or Placebo (PLA) with Gemcitabine (Gem) + Nab-paclitaxel (Nab) in Patients with Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Updated Results Including Planned Pooled Placebo Analysis." Annals of Oncology 36 (2025): S1233. https://doi.org/10.1016/j.annonc.2025.08.2836.

MLA (9th ed.) Citation

Dean, A., et al. "2219P AGITG ASCEND: Randomised, Double-blind Phase II Trial of Certepetide (CERT) or Placebo (PLA) with Gemcitabine (Gem) + Nab-paclitaxel (Nab) in Patients with Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Updated Results Including Planned Pooled Placebo Analysis." Annals of Oncology, vol. 36, 2025, p. S1233, https://doi.org/10.1016/j.annonc.2025.08.2836.